XOMA Royalty Corp. (XOMA)
41.82
-0.16
(-0.38%)
USD |
NASDAQ |
May 21, 16:00
41.85
+0.03
(+0.07%)
After-Hours: 19:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 524.46M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 66.48% |
| Valuation | |
| PE Ratio | 26.62 |
| PE Ratio (Forward) | |
| PS Ratio | 15.38 |
| Price to Book Value | 5.650 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 1.105 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 69.70% |
Profile
| XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA. |
| URL | http://www.xoma.com |
| Investor Relations URL | https://investors.xoma.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 13, 2026 (est.) |
| Last Earnings Release | May. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA. |
| URL | http://www.xoma.com |
| Investor Relations URL | https://investors.xoma.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 13, 2026 (est.) |
| Last Earnings Release | May. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |